secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001437749-24-017058
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma Q3 fiscal 2024 positive adjusted EBITDA $0.4M; ADHD revenue up 49% YoY
--------------------------------------------------------------------------------

- Q3 net loss $2.9M ($0.52/sh) vs $7.2M loss prior year; positive adjusted EBITDA $0.4M.
- ADHD Portfolio net revenue up 49% to $12.3M; Rx gross margin improved to 74%.
- Consumer Health net revenue down 56% to $4.0M; wind-down continues as planned.
- TTM companywide adjusted EBITDA positive $15.4M; Rx Business TTM adjusted EBITDA $17.1M.
- Cash $19.8M; manufacturing transition expected to improve margins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924017058/0001437749-24-017058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924017058/aytu20240223_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-017058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer